Medis QFR® continues to show superiority over standard angiography, after a FU-period of 2 years
In the September 2022 issue of JACC journals (https://www.jacc.org/doi/10.1016/j.jacc.2022.06.044), the FAVOR III China Study Group published a sub-study that was aimed to ascertain whether the beneficial outcomes of QFR® guidance for lesion selection during PCI is affected by diabetes status.
From the total of 3825 patients enrolled, 1295 (33.9%) had diabetes. The study confirmed that the QFR®-guided strategy consistently reduced the 1-year MAC in both diabetic (6.2% vs 9.6%) and non-diabetic (5.6% vs 8.3%) patients versus standard angiography. Among patients in whom PCI was deferred after QFR®, the 1-year MAC risk was similar in patients with and without diabetes (4.5% vs 6.2%). Conclusions: a QFR®-guided lesion selection strategy improves PCI outcomes compared with standard angiography guidance in patients both with and without diabetes.
This paper was accompanied by a very constructive Editorial Comment by Dr. Morton Kern and. Dr Arnold Seto. Fig. 1 (https://www.jacc.org/doi/10.1016/j.jacc.2022.07.020), shows that the annual number of publications on QFR® has now surpassed that of iFR, and that a sharp increase in clinical uptake is to be expected, much like what happened with FFR well after 2012, following the FAME and FAME 2 studies.
Share this article on: